Expert Highlights Testing Standards in Patients With Colorectal Cancer
Scott Kopetz, MD, associate professor of GI Medical Oncology at MD Anderson Center, advises community oncologists on what testing should be done for patients with colorectal cancer.
Scott Kopetz, MD, associate professor of GI Medical Oncology at MD Anderson Center, advises community oncologists on what testing should be done for patients with colorectal cancer (CRC).
Updated guidelines suggest microsatellite testing (MSI) for every patient with CRC regardless of their stage. This will help in discovering the available novel therapies for your patient, Kopetz said. Other testing for this patient population should include KRAS, NRAS, and BRAF, which is currently considered a standard in this field.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
